Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26758124 | 0.85 | MEN1 (0.52) | MEN1KMT2AABCC1ABCB1POLB | |
| SCHEMBL26758116 | 0.84 | ABCB1 (0.54) | MEN1KMT2AABCC1ABCB1POLB | |
| SCHEMBL26758117 | 0.84 | POLB (0.60) | MEN1KMT2AABCC1ABCB1POLB | |
| SCHEMBL24166137 | 0.84 | MET (0.48) | ABCC1POLBSMN1; SMN2HPGD | |
| SCHEMBL30656873 | 0.83 | MEN1 (0.48) | MEN1KMT2AABCC1ABCB1POLB | |
| SCHEMBL26758127 | 0.83 | MEN1 (0.48) | MEN1KMT2AABCC1ABCB1POLB | |
| SCHEMBL26758120 | 0.82 | MEN1 (0.67) | MEN1KMT2APOLBGAARECQL | |
| SCHEMBL26758131 | 0.82 | ABCC1 (0.50) | MEN1KMT2AABCC1ABCB1POLB | |
| SCHEMBL26758130 | 0.80 | ABCC1 (0.53) | MEN1KMT2AABCC1ABCB1POLB | |
| SCHEMBL30656772 | 0.80 | MEN1 (0.48) | MEN1KMT2AABCC1ABCB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | ATG7, GOT1, LIPC | MEN1 3700/4885KMT2A 3393/4885ABCC1 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.